Dosing recommendations for pharmacogenetic interactions related to drug metabolism

Pharmacogenetics and Genomics

Volumn 26, Issue 7, 2016, Pages 334-339

  Filipski, Kelly K ^a   Pacanowski, Michael A ^b   Ramamoorthy, Anuradha ^b   Feero, William Gregory ^c   Freedman, Andrew N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c Maine Dartmouth Family Practice Residency   (United States)

Author keywords

biomarkers; drug labeling; drug metabolizing enzymes; pharmacogenomics

Indexed keywords

AMITRIPTYLINE; ARIPIPRAZOLE; ATOMOXETINE; AZATHIOPRINE; BELINOSTAT; BIOLOGICAL MARKER; CAPECITABINE; CARISOPRODOL; CELECOXIB; CEVIMELINE; CITALOPRAM; CLOBAZAM; CLOMIPRAMINE; CLOPIDOGREL; CLOZAPINE; CODEINE; DESIPRAMINE; DEXTROMETHORPHAN; DRUG METABOLIZING ENZYME; ELIGLUSTAT; ESCITALOPRAM; FLUOROURACIL; FLUOXETINE; FLURBIPROFEN; ILOPERIDONE; IMIPRAMINE; IRINOTECAN; MERCAPTOPURINE; QUINIDINE; UNINDEXED DRUG; CYTOCHROME P450; DRUG;

ARTICLE; DRUG LABELING; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; UNITED STATES; ADVERSE DRUG REACTION; DOSE RESPONSE; DRUG MONITORING; GENETICS; METABOLISM;

BIOMARKERS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENOTYPE; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC;

EID: 84964061277     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000220     Document Type: Article

References (22)

1. Paugh SW, Stocco G, McCorkle JR, Diouf B, Crews KR, Evans WE. Cancer pharmacogenomics. Clin Pharmacol Ther 2011; 90: 461-466.
2. Coate L, Cuffe S, Horgan A, Hung RJ, Christiani D, Liu G. Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 2010; 28: 4029-4037.
3. Gillis NK, Patel JN, Innocenti F. Clinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era. Clin Pharmacol Ther 2014; 95: 269-280.
4. Pirmohamed M. Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin Pharmacol Ther 2010; 88: 862-866.
5. Mikat-Stevens NA, Larson IA, Tarini BA. Primary-care providers perceived barriers to integration of genetics services: a systematic review of the literature. Genet Med 2015; 17: 169-176.
6. Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 2012; 92: 87-95.
7. Weitzel KW, Elsey AR, Langaee TY, Burkley B, Nessl DR, Obeng AO, et al. Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet 2014; 166C: 56-67.
8. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther 2012; 91: 450-458.
9. US Food and Drug Administration. Drugs@FDA. Silver Spring, MD: US Department of Health and Human Services. Available at: http: //www. accessdata.fda.gov/scripts/cder/drugsatfda/.[Accessed 5 February 2016].
10. US National Library of Medicine. DailyMed. Bethesda, MD: US Department of Health and Human Services. Available at: http: //dailymed.nlm.nih.gov/.dailymed/about.cfm [Accessed 5 February 2016].
11. FDA. Table of pharmacogenomic biomarkers in drug labels, 2012. Available at: http: //www.fda.gov/drugs/scienceresearch/researchareas/.pharmacogenetics/ucm083378.htm. [Accessed 5 February 2016].
12. Agency for Healthcare Research and Quality. National Guideline Clearinghouse. Rockville, MD: US Department of Health and Human Services. Available at: http: //www.guideline.gov/.[Accessed 5 February 2016].
13. Evaluation of Genomic Applications in Practice and Prevention Working Group. Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med 2007; 9: 819-825.
14. [No authors listed]. Pharmacogenetic testing to predict serious toxicity from 5-fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer. Technol Eval Cent Assess Program Exec Summ 2010; 24: 1-3.
15. Evaluation of Genomic Applications in Practice and Prevention Working Group. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?. Genet Med 2009; 11: 15-20.
16. US Food and Drug Administration Clinical pharmacogenomics: premarket evaluation in early-phase clinical studies and recommendations for labeling 2013.
17. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl): e89S-e119S.
18. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter Cardiovasc Interv 2012 79 453-495.
19. Hicks JK, Swen JJ, Thorn CF, Sangkuhl K, Kharasch ED, Ellingrod VL, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93: 402-408.
20. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther 2011; 89: 464-467.
21. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med 2009; 11: 3-14.
22. Amstutz U, Carleton BC. Pharmacogenetic testing: time for clinical practice guidelines. Clin Pharmacol Ther 2011; 89: 924-927.